ImmunityBio (IBRX) said Wednesday it has received the US Food and Drug Administration's authorization for an expanded access program to provide recombinant Bacillus Calmette-Guerin, addressing the nationwide shortage of TICE BCG for bladder cancer treatment.
The alternative BCG, developed by the Serum Institute of India, has performed well in European trials for non-muscle invasive bladder cancer, exhibiting strong immunogenicity and enhanced safety over previous strains.
ImmunityBio said that rBCG supplies are now available, with shipments starting immediately through an FDA Expanded Access Program.
Shares of ImmunityBio were up more than 8% in recent Wednesday trading.
Price: 3.62, Change: +0.27, Percent Change: +8.06
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。